Literature DB >> 12114819

Genetic Changes in Chromosomes 1p and 17p in Thyroid Cancer Progression.

Celina G. Kleer1, Bonita R. Bryant, Thomas J. Giordano, Mark Sobel, Maria J. Merino.   

Abstract

Little is known about the genetic alterations that occur during the progression of thyroid neoplasms. To understand better the biology of thyroid tumors, we investigated several genetic loci in benign and malignant thyroid neoplasms. Forty-one thyroid tumors (6 adenomas, 16 papillary, 14 follicular, and 5 anaplastic carcinomas) were studied. Normal and tumor cells were microdissected from paraffin-embedded tissues. DNA was used for polymerase chain reaction-based loss of heterozygosity (LOH) analysis with the following markers: D1S243 (1p35-36), D1S165 (1p36) and D1S162 (1p32), TP53 (17p13), and INT-2 (11q13). Immunohistochemistry for Ki-67 was performed. The Ki-67 labeling index (LI) was the percentage of positive tumor cells. LOH at 1p was seen in 2 of 5 (40%) informative cases of anaplastic carcinoma (2 of 2 at D1S162 and 1 of 2 at D1S165) and in 2 of 11 (18%) informative cases of follicular carcinoma (2 of 7 at D1S243, 2 of 7 at D1S1654, and 1 of 6 at D1S162). One anaplastic (20%) and two follicular carcinomas (14%) had LOH in at least two of the 1p loci analyzed. None of the adenomas and papillary carcinomas had LOH at these loci. LOH at 17p and 11q13 were infrequent. Ki-67 LI was 1.4, 7, 16, and 65% in adenomas, papillary, follicular, and anaplastic carcinomas, respectively. Allelic loss at 1p may occur in aggressive types of thyroid carcinoma and may be a marker of poor prognosis. LOH at 1p may represent a late genetic event in thyroid carcinogenesis. LOH at 17p and 11q13 (MEN gene locus) is uncommon in thyroid neoplasms.

Entities:  

Year:  2000        PMID: 12114819     DOI: 10.1385/ep:11:2:137

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  27 in total

Review 1.  Clinical implications of the p53 tumor-suppressor gene.

Authors:  C C Harris; M Hollstein
Journal:  N Engl J Med       Date:  1993-10-28       Impact factor: 91.245

2.  Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype.

Authors:  M Santoro; F Carlomagno; I D Hay; M A Herrmann; M Grieco; R Melillo; M A Pierotti; I Bongarzone; G Della Porta; N Berger
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

3.  Detection of the PTC/retTPC oncogene in human thyroid cancers.

Authors:  S M Jhiang; D R Caruso; E Gilmore; Y Ishizaka; T Tahira; M Nagao; I M Chiu; E L Mazzaferri
Journal:  Oncogene       Date:  1992-07       Impact factor: 9.867

4.  High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma.

Authors:  I Bongarzone; M A Pierotti; N Monzini; P Mondellini; G Manenti; R Donghi; S Pilotti; M Grieco; M Santoro; A Fusco
Journal:  Oncogene       Date:  1989-12       Impact factor: 9.867

5.  A reciprocal translocation (1;15) (36.2;q24) in a neuroblastoma cell line is accompanied by DNA duplication and may signal the site of a putative tumor suppressor-gene.

Authors:  L C Amler; R Corvi; C Praml; L Savelyeva; D Le Paslier; M Schwab
Journal:  Oncogene       Date:  1995-03-16       Impact factor: 9.867

6.  Frequent loss of heterozygosity on chromosomes 3p and 17p without VHL or p53 mutations suggests involvement of unidentified tumor suppressor genes in follicular thyroid carcinoma.

Authors:  S K Grebe; B McIver; I D Hay; P S Wu; L M Maciel; H A Drabkin; J R Goellner; C S Grant; R B Jenkins; N L Eberhardt
Journal:  J Clin Endocrinol Metab       Date:  1997-11       Impact factor: 5.958

7.  Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland.

Authors:  T Ito; T Seyama; T Mizuno; N Tsuyama; T Hayashi; Y Hayashi; K Dohi; N Nakamura; M Akiyama
Journal:  Cancer Res       Date:  1992-03-01       Impact factor: 12.701

8.  A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases.

Authors:  A Fusco; M Grieco; M Santoro; M T Berlingieri; S Pilotti; M A Pierotti; G Della Porta; G Vecchio
Journal:  Nature       Date:  1987 Jul 9-15       Impact factor: 49.962

9.  Human colorectal cancer: high frequency of deletions at chromosome 1p35.

Authors:  I Leister; A Weith; S Brüderlein; C Cziepluch; D Kangwanpong; P Schlag; M Schwab
Journal:  Cancer Res       Date:  1990-11-15       Impact factor: 12.701

10.  p53 gene mutations associated with anaplastic transformation of human thyroid carcinomas.

Authors:  T Nakamura; I Yana; T Kobayashi; E Shin; K Karakawa; S Fujita; A Miya; T Mori; I Nishisho; S Takai
Journal:  Jpn J Cancer Res       Date:  1992-12
View more
  10 in total

1.  Cancer risks for monoallelic MUTYH mutation carriers with a family history of colorectal cancer.

Authors:  Aung Ko Win; Sean P Cleary; James G Dowty; John A Baron; Joanne P Young; Daniel D Buchanan; Melissa C Southey; Terrilea Burnett; Patrick S Parfrey; Roger C Green; Loïc Le Marchand; Polly A Newcomb; Robert W Haile; Noralane M Lindor; John L Hopper; Steven Gallinger; Mark A Jenkins
Journal:  Int J Cancer       Date:  2011-04-08       Impact factor: 7.396

Review 2.  Throwing the cancer switch: reciprocal roles of polycomb and trithorax proteins.

Authors:  Alea A Mills
Journal:  Nat Rev Cancer       Date:  2010-10       Impact factor: 60.716

3.  The tumor suppressor Chd5 is induced during neuronal differentiation in the developing mouse brain.

Authors:  Assaf Vestin; Alea A Mills
Journal:  Gene Expr Patterns       Date:  2013-10-09       Impact factor: 1.224

4.  Mig-6 controls EGFR trafficking and suppresses gliomagenesis.

Authors:  Haoqiang Ying; Hongwu Zheng; Kenneth Scott; Ruprecht Wiedemeyer; Haiyan Yan; Carol Lim; Joseph Huang; Sabin Dhakal; Elena Ivanova; Yonghong Xiao; Hailei Zhang; Jian Hu; Jayne M Stommel; Michelle A Lee; An-Jou Chen; Ji-Hye Paik; Oreste Segatto; Cameron Brennan; Lisa A Elferink; Y Alan Wang; Lynda Chin; Ronald A DePinho
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-29       Impact factor: 11.205

5.  Tumor heterogeneity in a follicular carcinoma of thyroid: a study by comparative genomic hybridization.

Authors:  Leonard Da Silva; Daniel James; Peter T Simpson; Daniel Walker; Ana Cristina Vargas; Janani Jayanthan; Sunil R Lakhani; Anne Marie McNicol
Journal:  Endocr Pathol       Date:  2011-06       Impact factor: 3.943

Review 6.  Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas.

Authors:  Yuri E Nikiforov
Journal:  Endocr Pathol       Date:  2004       Impact factor: 3.943

7.  Constitutive short telomere length of chromosome 17p and 12q but not 11q and 2p is associated with an increased risk for esophageal cancer.

Authors:  Jinliang Xing; Jaffer A Ajani; Meng Chen; Julie Izzo; Jie Lin; Zhinan Chen; Jian Gu; Xifeng Wu
Journal:  Cancer Prev Res (Phila)       Date:  2009-04-28

Review 8.  The quest for the 1p36 tumor suppressor.

Authors:  Anindya Bagchi; Alea A Mills
Journal:  Cancer Res       Date:  2008-04-15       Impact factor: 12.701

9.  Silencing of CHD5 gene by promoter methylation in leukemia.

Authors:  Rui Zhao; Fanyi Meng; Nisha Wang; Wenli Ma; Qitao Yan
Journal:  PLoS One       Date:  2014-01-13       Impact factor: 3.240

10.  Clinicopathological Significance of Overall Frequency of Allelic Loss (OFAL) in Lesions Derived from Thyroid Follicular Cell.

Authors:  Monika Migdalska-Sęk; Karolina H Czarnecka; Michał Kusiński; Dorota Pastuszak-Lewandoska; Ewa Nawrot; Krzysztof Kuzdak; Ewa Brzeziańska-Lasota
Journal:  Mol Diagn Ther       Date:  2019-06       Impact factor: 4.074

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.